Pembrolizumab/Cabozantinib Combo Provides Benefit in mRCC
June 9th 2021The combination of pembrolizumab and cabozantinib induced a response in more than half of patients with metastatic renal cell carcinoma at the recommended phase 2 dose with a manageable safety profile, meeting the primary end point of a phase 1/2 trial.